natgillin/translations-raw huggingface dataset:
Meget almindelig (≥ 1/ 10), almindelig (≥ 1/ 100 til < 1/ 10), ikke almindelig (≥ 1/ 1. 000 til < 1/ 100), sjælden (≥ 1/ 10. 000 til < 1/ 1. 000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Frequencies are defined as: very common (≥ 1/ 10), common (≥ 1/ 100 to < 1/ 10), uncommon (≥ 1/ 1,000 to < 1/ 100), rare (≥ 1/ 10,000 to < 1/ 1,000), not known (cannot be estimated from the available data).
Blod/ lymfe
Common Haematological / Lymphatic
Blødning fra slimhinder, forlænget blødningstid, trombocytopeni, bloddyskrasier, (inkl. agranulocytose, aplastisk anæmi, neutropeni og pancytopeni)
Mucous membrane bleeding, Prolonged bleeding time, Thrombocytopaenia, Blood dyscrasias, (including agranulocytosis, aplastic anaemia, neutropaenia and pancytopaenia)
Stofskifte / ernæring
Metabolic/ Nutritional
Abnorme lever - funktionsprøver, hyponatriæmi, hepatitis, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), øget prolaktin
Abnormal liver function tests, Hyponatraemia, Hepatitis, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), Prolactin increased
29 Organsystem
30 Body System
Nervesystem
Common Nervous
Mundtør - hed (10, 0%), hovedpine (30, 3%) *
Dry mouth (10.0%), Headache (30.3%)*
Akatisi / psyko - motorisk rastløshed, kramper, manisk reaktion
Akathisia/ Psychomotor restlessness, Convulsion, Manic reaction
Neuroleptisk malignt syndrom (NMS), serotonin - syndrom, delirium, ekstrapyramidale reaktioner (inkl. dystoni og dyskinesi), tardive dyskinesier, suicidale forestillinger og adfærd **
Neuroleptic Malignant Syndrome (NMS), Serotonergic syndrome, Delirium, Extrapyramidal reactions (including dystonia and dyskinaesia), Tardive dyskinaesia, Suicidal ideation and behaviours**
Ændret smags - fornemmelse, tinnitus
Altered taste sensation, Tinnitus
Hypertension, vasodilatation (fortrinsvis hedestig - ninger / rødmen), hjertebanken
Hypertension, Vasodilatation (mostly hot flashes/ flushes), Palpitations
Hypotension, QT- forlængelse, ventrikelflimren, ventrikulær takykardi (inkl. torsade de pointes)
Hypotension, QT prolongation, Ventricular fibrillation, Ventricular tachycardia (including torsade de pointes)
Fordøjelse
Digestive
Kvalme (20, 0%)
Nausea (20.0%)
Perspiration (inkl. nattesved) [12, 2%]
Sweating (includin g night sweats) [12.2%]
Erythema multiforme, toksisk epidermal nekrolyse, Stevens- Johnsons syndrom, pruritus, urticaria
Erythema multiforme, Toxic epidermal necrolysis, Stevens- Johnson syndrome, Pruritus, Urticaria
Muskolo - skeletalt
Musculoskeletal
30 Organsystem
31 Body System
Lidelser i nyrer og urinveje
Common Urogenital
Abnorm sædafgang/ orgasme (mænd), anorgasme, erektil dysfunktion (impotens), vandladningsproblemer (ofte startbesvær), menstruationsforstyrrelse r med forøget blødning eller forøget, uregelmæssig blødning (f. eks. menoragi, metroragi), pollakiuria
Abnormal ejaculation/ orgas m (males), Anorgasmia, Erectile dysfunction (impotence), Urination impaired (mostly hesitancy), Menstrual disorders associated with increased bleeding or increased irregular bleeding (e. g., menorrhagia, metrorrhagia), Pollakiuria
Lysoverfølsom - hedsreaktion
Photosensitivit y reaction
4. 4).
*In pooled clinical trials, the incidence of headache was 30.3% with venlafaxine versus 31.3% with placebo. **Cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy or early after treatment discontinuation (see section 4.4).
Svimmelhed, føleforstyrrelser (inkl. paræstesi), søvnforstyrrelser (inkl. insomni og voldsomme drømme), agitation eller angst, kvalme og/ eller opkastning, rysten, hovedpine og influenzasyndrom er de mest almindelige, indberettede reaktioner.
Dizziness, sensory disturbances (including paraethesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/ or vomiting, tremor, headache and flu syndrome are the most commonly reported reactions.
Generelt er disse tilfælde milde til moderate og er selvbegrænsende, men hos nogle patienter kan de dog være alvorlige og/ eller vare længere tid.
Generally, these events are mild to moderate and are self-limiting; however, in some patients, they may be severe and/ or prolonged.
4. 2 og 4. 4).
Paediatric patients
Pædiatriske patienter Generelt var venlafaxins bivirkningsprofil (i placebo- kontrollerede kliniske forsøg) hos børn og unge (i alderen 6 til 17 år) den samme som hos voksne.
In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical trials) in children and adolescents (ages 6 to 17) was similar to that seen for adults.
4. 4).
As with adults, decreased appetite, weight loss, increased blood pressure, and increased serum cholesterol were observed (see section 4.4).
Ved erfaringerne efter markedsføring blev overdosering med venlafaxin fortrinsvis rapporteret i kombination med alkohol og/ eller andre lægemidler.
In postmarketing experience, overdose with venlafaxine was reported predominantly in combination with alcohol and/ or other medicinal products.
Andre rapporterede hændelser omfatter:
32 convulsion, and vomiting.
EKG- ændringer (f. eks. forlængelse af QT- intervallet, grenblok, QRS- forlængelse), ventrikulær takykardi, bradykardi, hypotension, vertigo og dødsfald.
Other reported events include electrocardiographic changes (e. g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia, bradycardia, hypotension, vertigo, and death.
Offentliggjorte, retrospektive forsøg rapporterer, at overdosering af venlafaxin kan være forbundet med en forhøjet risiko for dødelig udgang i forhold til det, der ses med SSRI- antidepressiva, men lavere end for tricykliske antidepressiva.
Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants.
Epidemiologiske forsøg har påvist, at patienter, som behandles med venlafaxin, har en større byrde af selvmordsrisikofaktorer end SSRI- patienter.
The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristics of venlafaxine-treated patients, is not clear.
I hvor høj grad fundet af en forhøjet risiko for dødelig udgang kan tilskrives venlafaxins toksicitet ved
Prescriptions for venlafaxine should be written for the smallest quantity of the medicinal product consistent with good patient management in order to reduce the risk of overdose.
31 overdosering i modsætning til en række karakteristika hos patienter, som behandles med venlafaxin, er ikke klart.
Recommended treatment
Anbefalet behandling Det anbefales at yde generel symptomatisk behandling og støtteforanstaltninger.
General supportive and symptomatic measures are recommended; cardiac rhythm and vital signs must be monitored.
Andre antidepressiva - ATC- kode:
Other antidepressants - ATC code:
Prækliniske undersøgelser har vist, at venlafaxin og dets hovedmetabolit, O- desmethylvenlafaxin (ODV), hæmmer serotonin og noradrenalin genoptag.
Preclinical studies have shown that venlafaxine and its major metabolite, O-desmethylvenlafaxine (ODV), are inhibitors of serotonin and noradrenaline reuptake.
Venlafaxin og dets aktive metabolit reducerer den β- adrenerge modtagelighed efter både akut (enkeltdosis) og kronisk administration.
Venlafaxine and its active metabolite reduce β -adrenergic responsiveness after both acute (single dose) and chronic administration.
Venlafaxin og ODV er meget ens med hensyn til deres samlede virkning på neurotransmitter- genoptag og receptorbinding.
Venlafaxine and ODV are very similar with respect to their overall action on neurotransmitter reuptake and receptor binding.
Venlafaxin har så godt som ingen affinitet for muskarine, kolinerge, H1- histaminerge eller α1- adrenerge receptorer in vitro.
Venlafaxine has virtually no affinity for rat brain muscarinic, cholinergic, H1-histaminergic or α 1-adrenergic receptors in vitro.
Venlafaxin har ingen MAO- hæmmende aktivitet.
Venlafaxine does not possess monoamine oxidase (MAO) inhibitory activity.
In vitro- forsøg viste, at venlafaxin så godt som ikke har nogen affinitet for opiater eller benzodiazepinfølsomme receptorer.
In vitro studies revealed that venlafaxine has virtually no affinity for opiate or benzodiazepine sensitive receptors.
Virkningen af venlafaxin med umiddelbar udløsning til behandling af større depressive episoder blev fastlagt i 5 randomiserede, dobbeltblinde, placebo- kontrollerede, kortvarige forsøg af 4 til 6 ugers varighed, med doser op til 375 mg/ dag.
The efficacy of venlafaxine prolonged-release as a
Virkningen af venlafaxin depot til behandling af større depressive episoder blev fastlagt i 2 placebo- kontrollerede, kortvarige forsøg af 8 og12 ugers varighed, med doser fra 75 til 225 mg/ dag.
33 treatment for major depressive episodes was established in two placebo-controlled, short-term studies for 8 and 12 weeks duration, which included a dose range of 75 to 225 mg/ day.
I et længerevarende forsøg blev voksne ambulante patienter, som under et 8- ugers åbent forsøg havde responderet på venlafaxin depot (75, 150, eller 225 mg, hver morgen), randomiseret til enten at fortsætte på den samme venlafaxin depot- dosis eller til placebo med henblik på op til 26 ugers observation for recidiv.
In one longer-term study, adult outpatients who had responded during an 8-week open trial on venlafaxine prolonged-release (75, 150, or 225 mg) were randomised to continuation of their same venlafaxine prolonged-release dose or to placebo, for up to 26 weeks of observation for relapse.
I et andet længerevarende forsøg blev virkningen af venlafaxin til forebyggelse af nye anfald af depressive episoder i en 12- måneders periode fastslået i et placebo- kontrolleret, dobbeltblindt klinisk forsøg med voksne ambulante patienter med tilbagevendende større depressive episoder, som havde responderet på venlafaxinbehandling (100 til 200 mg dagligt, to gange dagligt) under den sidste depressionsepisode.
In a second longer-term study, the efficacy of venlafaxine in prevention of recurrent depressive episodes for a 12-month period was established in a placebo-controlled double-blind clinical trial in adult outpatients with recurrent major depressive episodes who had responded to venlafaxine treatment (100 to 200 mg/ day, on a b. i. d. schedule) on the last episode of depression.
32 Generaliseret angst Virkningen af venlafaxin depotkapsler til behandling af generaliseret angst (GAD) hos voksne ambulante patienter er fastslået i to 8- ugers placebo- kontrollerede forsøg med fast dosis (75 til 225 mg/ dag), et 6- måneders placebo- kontrolleret forsøg med fast dosis (75 til 225 mg/ dag) og et 6 - måneders placebo- kontrolleret forsøg med fleksibel dosis (37, 5, 75 og 150 mg/ dag).
The efficacy of venlafaxine prolonged-release capsules as a treatment for generalised anxiety disorder (GAD) was established in two 8-week, placebo-controlled, fixed-dose studies (75 to 225 mg/ day), one 6-month, placebo-controlled, fixed-dose study (75 to 225 mg/ day), and one 6-month, placebo-controlled, flexible-dose study (37.5, 75, and 150 mg/ day) in adult outpatients.
Selv om der også var evidens for, at en dosis på 37. 5 mg/ dag var bedre end placebo, var denne dosis ikke så konsekvent effektiv som de højere doser.
While there was also evidence for superiority over placebo for the 37.5 mg/ day dose, this dose was not as consistently effective as the higher doses.
Socialfobi Virkningen af venlafaxin depotkapsler til behandling af socialfobi hos voksne ambulante patienter er fastslået i fire dobbeltblinde, parallel- gruppe -, 12- ugers multicenter, placebo- kontrollerede forsøg med fleksibel dosis og et dobbeltblindt, parallel- gruppe -, 6- måneders placebo- kontrolleret forsøg med fast/ fleksibel dosis.
The efficacy of venlafaxine prolonged-release capsules as a treatment for social anxiety disorder was established in four double-blind, parallel-group, 12-week, multi-center, placebo-controlled, flexible-dose studies and one double-blind, parallel-group, 6-month, placebo-controlled, fixed/ flexible-dose study in adult outpatients.
Patienterne fik doser på mellem 75 og 225 mg/ dag.
Patients received doses in a range of 75 to 225 mg/ day.
Der var ingen evidens for større effektivitet hos gruppen, som fik 150 til 225 mg/ dag, sammenlignet med gruppen, som fik 75 mg/ dag i forsøget over 6 måneder.
There was no evidence for any greater effectiveness of the 150 to 225 mg/ day group compared to the 75 mg/ day group in the 6-month study.
Panikangst Virkningen af venlafaxin depotkapsler til behandling af panikangst hos voksne ambulante patienter med panikangst med eller uden agorafobi er fastslået i to dobbeltblinde, 12- ugers multicenter, placebo- kontrollerede forsøg.
The efficacy of venlafaxine prolonged-release capsules as a treatment for panic disorder was established in two double-blind, 12-week, multi-center, placebo-controlled studies in adult outpatients with panic disorder, with or without agoraphobia.
Initialdosis i forsøgene med panikangst var 37, 5 mg/ dag i 7 dage.
The initial dose in panic disorder studies was 37.5 mg/ day for 7 days.
Derefter fik patienterne en fast dosis på 75 eller 150 mg/ dag i det ene forsøg og 75 til 225 mg/ dag i det andet forsøg.
Patients then received fixed doses of 75 or 150 mg/ day in one study and 75 or 225 mg/ day in the other study.
Virkningen med hensyn til langtidssikkerhed, effekt og forebyggelse af tilbagefald blev også fastslået i et langtids -, dobbeltblindt, placebo- kontrolleret parallel- gruppe- forsøg med voksne ambulante patienter, som responderede på åben behandling.
Efficacy was also established in one long-term double-blind, placebo-controlled, parallel-group study of the long-term safety, efficacy, and prevention of relapse in adult outpatients who responded to open-label treatment.
Venlafaxin metaboliseres i omfattende grad, primært til den aktive metabolit, O- desmethylvenlafaxin (ODV).
Venlafaxine is extensively metabolised, primarily to the active metabolite, O-desmethylvenlafaxine (ODV).
Venlafaxins og ODVs middel ± SD plasma- halveringstid er henholdsvis 5 ±2 timer og 11 ±2 timer.
Mean ± SD plasma half-lives of venlafaxine and ODV are 5±2 hours and 11±2 hours, respectively.
Steady state- koncentrationer af venlafaxin og ODV nås inden for 3 dages behandling med multiple orale doser.
Steady-state concentrations of venlafaxine and ODV are attained within 3 days of oral multiple-dose therapy.
Venlafaxin og ODV udviser lineær kinetik gennem dosisintervallet fra 75 mg til 450 mg dagligt.
Venlafaxine and ODV exhibit linear kinetics over the dose range of 75 mg to 450 mg/ day.
Absorption Mindst 92% venlafaxin absorberes efter enkelte orale doser venlafaxin til umiddelbar udløsning.
At least 92% of venlafaxine is absorbed following single oral doses of immediate-release venlafaxine.
Absolut biotilgængelighed er 40% til 45% på grund af præsystemisk metabolisme.
Absolute bioavailability is 40% to 45% due to presystemic metabolism.
Efter administration af venlafaxin depotkapsler nås de højeste plasmakoncentrationer af venlafaxin og ODV inden for henholdsvis 5, 5 timer og 9 timer.
Following the administration of venlafaxine prolonged-release capsules, peak plasma concentrations of venlafaxine and ODV are attained within 5.5 hours and 9 hours, respectively.
Fordeling Venlafaxin og ODV binder sig minimalt til humane plasmaproteiner ved terapeutiske koncentrationer (henholdsvis 27% og 30%).
Venlafaxine and ODV are minimally bound at therapeutic concentrations to human plasma proteins (27% and 30%, respectively).
Venlafaxins fordelingsvolumen ved steady state er 4, 4 ±1, 6 l/ kg efter intravenøs administration.
The volume of distribution for venlafaxine at steady-state is 4.4±1.6 L/ kg following intravenous administration.
Metabolisering Venlafaxin gennemgår en omfattende hepatisk metabolisering.
Venlafaxine undergoes extensive hepatic metabolism.
In vitro - og in vivo -
In vitro and in vivo studies indicate that venlafaxine is biotransformed to its major active metabolite, ODV, by CYP2D6.
33 forsøg viser, at venlafaxin metaboliseres til en underordnet, mindre aktiv metabolit, N- desmethylvenlafaxin, af CYP3A4.
In vitro and in vivo studies indicate that venlafaxine is metabolised to a minor, less active metabolite, N-desmethylvenlafaxine, by CYP3A4.
In vitro - og in vivo- forsøg viser, at venlafaxin er en svag hæmmer af CYP2D6.
In vitro and in vivo studies indicate that venlafaxine is a weak inhibitor of CYP2D6.
Elimination Venlafaxin og dens metabolitter udskilles hovedsageligt via nyrerne.
Venlafaxine and its metabolites are excreted primarily through the kidneys.
Omtrent 87% af en venlafaxindosis genfindes i urinen inden for 48 timer som enten uændret venlafaxin (5%), ukonjugeret ODV (29%), konjugeret ODV (26%) eller andre underordnede inaktive metabolitter (27%).
Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).
Middel ± SD plasma steady state clearance for venlafaxin og ODV er henholdsvis 1, 3 ±0, 6 l/ t/ kg og 0, 4 ±0, 2 l/ t/ kg.
Mean ± SD plasma steady-state clearances of venlafaxine and ODV are 1.3±0.6 L/ h/ kg and 0.4±0.2 L/ h/ kg, respectively.
Personer med god og ringe CYP2D6- metaboliseringsevne Plasmakoncentrationerne af venlafaxin er højere hos personer, som har en ringe CYP2D6 - metaboliseringsevne end hos personer, som har en god metaboliseringsevne.
CYP2D6 extensive/ poor metabolisers Plasma concentrations of venlafaxine are higher in CYP2D6 poor metabolisers than extensive metabolisers.
Patienter med nedsat leverfunktion Hos forsøgspersoner med Child- Pugh A (let nedsat leverfunktion) og Child- Pugh B (moderat nedsat leverfunktion) blev halveringstiden for venlafaxin og ODV forlænget i forhold til raske forsøgspersoner.
The oral
Både clearance for oralt venlafaxin og ODV blev reduceret.
35 clearance of both venlafaxine and ODV was reduced.
4. 2).
There are limited data in patients with severe hepatic impairment (see section 4.2).
56%.
Patients with renal impairment In dialysis patients, venlafaxine elimination half-life was prolonged by about 180% and clearance reduced by about 57% compared to normal subjects, while ODV elimination half-life was prolonged by about 142% and clearance reduced by about 56%.
4. 2).
Dosage adjustment is necessary in patients with severe renal impairment and in patients that require haemodialysis (see section 4.2).
Venlafaxin var ikke mutagent i en lang række in vitro - og in vivo- test.
Venlafaxine was not mutagenic in a wide range of in vitro and in vivo tests.
Disse virkninger indtraf ved 30 mg/ kg/ dag, 4 gange den humane daglige dosis på 375 mg venlafaxin (på en mg/ kg basis).
These effects occurred at 30 mg/ kg/ day, 4 times the human daily dose of 375 mg of venlafaxine (on an mg/ kg basis).
Dosis uden effekt i disse fund var 1, 3 gange human dosis.
The no-effect dose for these findings was 1.3 times the human dose.
Nedsat fertilitet blev observeret i et forsøg, hvor både han - og hunrotter blev eksponeret for ODV.
Reduced fertility was observed in a study in which both male and female rats were exposed to ODV.
1- 2 gange højere end en human venlafaxindosis på 375 mg dagligt.
This exposure was approximately 1 to 2 times that of a human venlafaxine dose of 375 mg/ day.
34 6.
6.
DD/ MM/ ÅÅÅÅ
{DD/ MM/ YYYY}
MM/ ÅÅÅÅ
{MM/ YYYY
35 [Udfyldes nationalt]
[To be completed nationally]
37 MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE OG PÅ DEN INDRE EMBALLAGE
37 LABELLING
KARTON/ DÅSE
CARTON/ BOTTLE
Efexor Depot og tilhørende navne (se bilag I) 37. 5 mg depotkapsler, hårde
Efexor depot and associated names (see Annex I) 37.5 mg prolonged-release capsules, hard
39 MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE OG PÅ DEN INDRE EMBALLAGE
40 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Efexor Depot og tilhørende navne (se bilag I) 75 mg depotkapsler, hårde
Efexor depot and associated names (see Annex I) 75 mg prolonged-release capsules, hard
41 MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE OG PÅ DEN INDRE EMBALLAGE
42 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Efexor Depot og tilhørende navne (se bilag I) 150 mg depotkapsler, hårde
Efexor depot and associated names (see Annex I) 150 mg prolonged-release capsules, hard
[Udfyldes nationalt]
43 [To be completed nationally]
43 MINDSTEKRAV TIL MÆRKNING PÅ BLISTERKORT ELLER BLISTERSTRIPS
44 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Efexor Depot og tilhørende navne (se bilag I) 37. 5 mg depotkapsler
Efexor depot and associated names (see Annex I) 37.5 mg prolonged-release capsules
Efexor Depot og tilhørende navne (se bilag I) 75 mg depotkapsler
Efexor depot and associated names (see Annex I) 75 mg prolonged-release capsules
Efexor Depot og tilhørende navne (se bilag I) 150 mg depotkapsler
Efexor depot and associated names (see Annex I) 150 mg prolonged-release capsules
47 INDLÆGSSEDDEL:
47 PACKAGE LEAFLET
Efexor Depot og tilhørende navne (se bilag I) 37. 5 mg depotkapsler, hårde Efexor Depot og tilhørende navne (se bilag I) 75 mg depotkapsler, hårde Efexor Depot og tilhørende navne (se bilag I) 150 mg depotkapsler, hårde
Efexor depot and associated names (see Annex I) 37.5 mg prolonged-release capsules, hard Efexor depot and associated names (see Annex I) 75 mg prolonged-release capsules, hard Efexor depot and associated names (see Annex I) 150 mg prolonged-release capsules, hard
Du kan få brug for at læse den igen. • Spørg lægen eller på apoteket, hvis der er mere, du vil vide. • Lægen har ordineret denne medicin til dig personligt.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. • Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller du får bivirkninger, som ikke er nævnt her.
It may harm them, even if their symptoms are the same than yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Efexor Depots virkning og hvad du skal bruge det til 2.
What Efexor depot is and what is used for 2.
Det skal du vide, før du begynder at tage Efexor Depot 3.
Before you take Efexor depot 3.
Sådan skal du tage Efexor Depot 4.
How to take Efexor depot 4.
Sådan opbevarer du Efexor Depot 6.
How to store Efexor depot 6.
Efexor Depot er et antidepressivum, som tilhører en gruppe medicin, der kaldes serotonin - og noradrenalin- reuptake- hæmmere (SNRI’ er).
Efexor depot is an antidepressant that belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs).
Det menes, at personer, som er deprimerede og/ eller angste, har et lavere niveau af serotonin og noradrenalin i hjernen.
It is thought that people who are depressed and/ or anxious have lower levels of serotonin and noradrenaline in the brain.
Generaliseret angst, socialfobi (frygt for eller undgåelse af sociale situationer), panikangst (panikanfald).
Efexor depot is also a treatment for adults with the following anxiety disorders: generalised anxiety disorder, social anxiety disorder (fear or avoidance of social situations) and panic disorder (panic attacks).
Tag ikke Efexor Depot
Do not take Efexor depot
- Hvis du også tager eller inden for de sidste 14 dage har taget nogen form for medicin, der
• If you are allergic to venlafaxine or any of the other ingredients of Efexor depot. • If you are also taking or have taken any time within the last 14 days any medicines known as irreversible monoamine oxidase inhibitors (MAOIs), used to treat depression or Parkinson’ s disease.
Hvis du tager en irreversibel MAO- hæmmer sammen med anden medicin, herunder også Efexor Depot, kan det give alvorlige eller endda livstruende bivirkninger.
Taking an irreversible MAOI together with other medicines, including Efexor depot, can cause serious or even life-threatening side effects.